These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32594283)

  • 41. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
    Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
    Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study.
    Laufs U; Birkenfeld AL; Fraass U; Hohenstein B; Siegert C; Klotsche J; Steinhagen-Thiessen E; Pittrow D; Dexl S; Salmen S; Schettler VJJ; Parhofer KG;
    Cardiovasc Drugs Ther; 2024 Feb; 38(1):119-129. PubMed ID: 36178485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
    Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
    Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.
    Inoue K; Figueroa JF; DeJong C; Tsugawa Y; Orav EJ; Shen C; Kazi DS
    Circ Cardiovasc Qual Outcomes; 2021 May; 14(5):e007521. PubMed ID: 33966446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans.
    Derington CG; Colantonio LD; Herrick JS; Cook J; King JB; Rosenson RS; Poudel B; Monda KL; Navar AM; Mues KE; Stevens VW; Nelson RE; Vanneman ME; Muntner P; Bress AP
    J Am Heart Assoc; 2021 Apr; 10(8):e019254. PubMed ID: 33821686
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome.
    Moroni F; Ayers MP; Dixon DL; Abbate A
    J Cardiovasc Pharmacol; 2023 May; 81(5):336-338. PubMed ID: 37043382
    [No Abstract]   [Full Text] [Related]  

  • 49. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease.
    Dayoub EJ; Eberly LA; Nathan AS; Khatana SAM; Adusumalli S; Navar AM; Giri J; Groeneveld PW
    J Am Heart Assoc; 2021 May; 10(9):e019331. PubMed ID: 33904340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors.
    Shaw PB
    Am J Manag Care; 2021 Mar; 27(4 Suppl):S63-S69. PubMed ID: 33710845
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
    Mancini GBJ; Gupta M; Tsigoulis M; Cannon CP; Genest J; Ray KK; Santos RD; Watts GF; Raggi P
    Atherosclerosis; 2017 Aug; 263():112-118. PubMed ID: 28623740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Consensus statement of professional associations on prescribing of PCSK9-inhibitors.
    Češka R; Táborský M; Vrablík M
    Vnitr Lek; 2019; 64(12):1131-1136. PubMed ID: 30704246
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model.
    Donald DR; Reynolds VW; Hall N; DeClercq J; Choi L
    J Clin Lipidol; 2022; 16(3):315-324. PubMed ID: 35367164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction.
    Colantonio LD; Deng L; Chen L; Farkouh ME; Monda KL; Harrison DJ; Maya JF; Kilgore ML; Muntner P; Rosenson RS
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):601-610. PubMed ID: 30446883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Are PCSK9 Inhibitors Cost Effective?
    Korman MJ; Retterstøl K; Kristiansen IS; Wisløff T
    Pharmacoeconomics; 2018 Sep; 36(9):1031-1041. PubMed ID: 29777433
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-Need Phenotypes in Medicare Beneficiaries: Drivers of Variation in Utilization and Outcomes.
    Keeney T; Belanger E; Jones RN; Joyce NR; Meyers DJ; Mor V
    J Am Geriatr Soc; 2020 Jan; 68(1):70-77. PubMed ID: 31454082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.